Mr. More joined Domain Associates as a Kauffman Fellow in 1996, and he became a Partner in 2000. Present board memberships include Achaogen, Acureon Pharmaceuticals, Apnex Medical, Carticept Medical, Evoke Pharma, Glaukos, Lipothera, Novalar Pharmaceuticals, OmniSonics Medical Technologies and TargetRx. Past board memberships include ESP Pharma (acquired by Protein Design Labs, Inc.), Proxima Therapeutics (acquired by Cytyc Corporation), Onux Medical (acquired by C.R. Bard), NovaCardia (acquired by Merck), and Esprit Pharma (acquired by Allergan). Mr. More was also responsible for Domain’s investment in IntraLase (acquired by Advanced Medical Optics, Inc.). Additionally, Mr. More served as a Founding board member for Kauffman Fellows Program and serves as an Advisory board member for Montagu Newhall Associates, Okapi Ventures, The Medical Industry Group of the NVCA and The Sulpizio Family Cardiovascular Center. From 1997-1998, Mr. More served as the Chief Operating Officer of Small Molecule Therapeutics, a Domain portfolio company subsequently purchased by Morphochem AG. From 1992 to 1995, Mr. More was with Pharmacia Biotech in sales. Prior to joining Pharmacia, Mr. More held a research position at Somatogen, a company developing a recombinant blood substitute that was subsequently bought by Baxter. While attending business school, Mr. More worked with MedVest, an early-stage venture group in Washington, D.C.